CytomX Therapeutics

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytomX Therapeutics reports robust financials and strategic pipeline advancements

CytomX Therapeutics showcased strong financial performance, with a focus on advancing key therapeutic programs and collaborations with industry partners. The company's strategic capital allocation supports pipeline development, while challenges include program prioritization and industry competition. Opportunities for growth exist in advancing pipeline milestones and leveraging collaborations for innovation.

CytomX reports robust Q1 earnings, advances pipeline with key partners

CytomX Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2023
The company's strategic collaborations and focus on innovation position it for future growth
Balancing expenses, regulatory milestones, and clinical progress are key challenges and opportunities
Overall, CytomX is well-positioned to drive value through its transformative therapies

CytomX advances pipeline and partnerships, poised for growth in oncology

CytomX Therapeutics demonstrated strong performance, financial stability, and strategic partnerships in Q2 2023, signaling a promising outlook for future growth.
The company's focus on localized therapies, leadership team strength, and diverse pipeline underscore its competitive position in the biopharmaceutical industry.
While facing challenges in a competitive landscape, CytomX has opportunities for growth through innovative programs, partnerships, and alignment with industry trends.

CytomX Therapeutics reports strong Q3 earnings and outlines strategic roadmap

CytomX Therapeutics showcased solid financial performance in Q3 2023 with revenue of $26.4 million and prudent cost management.
The company's focus on cancer medicines and pipeline advancements position it well for future growth and market competitiveness.
While facing challenges in data updates and cost balancing, strategic milestones and opportunities for collaborations offer avenues for expansion.
Overall, CytomX Therapeutics remains well-positioned in the oncology sector with a strong cash position and promising pipeline candidates.

CytomX posts robust Q4 results, poised for growth in 2024

CytomX Therapeutics delivered a strong performance in Q4 2023, showcasing financial stability, progress on its Probody platform, and strategic partnerships to drive innovation.
While facing challenges in clinical development and partnership dynamics, the company's strengths in product pipeline diversity and financial management offer a solid foundation for future growth.
With exciting opportunities ahead, including upcoming data readouts and advancements in immunotherapy, CytomX is well-positioned to capitalize on its expertise in antibody masking and conditional activation.

CytomX reports positive Phase Ia data for CX-904 therapy

CytomX Therapeutics showcases strong performance with promising drug data.
Company's financial stability and innovative platform position it well for growth.
Challenges in translating research to clinical outcomes and predicting patient responses.
Opportunities lie in expanding drug potential, exploring combination strategies, and addressing assay challenges.

CytomX reports strong Q3 results, advances promising oncology therapies

CytomX Therapeutics delivered solid financial performance in Q3 2024 with a focus on key oncology programs.
The company's Probody platform shows promise in addressing unmet medical needs in various cancers.
Challenges lie in optimizing dose escalation, enrollment, and expansion of therapies to maximize impact.
Strategic partnerships and disciplined capital allocation position CytomX for future growth and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it plans to outline its pipeline priorities for 2023 and provide a data update for the CX-2029 Phase 2 cohort expansion study, on Thursday, January 5, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss updates.

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:00 p.m. ET.

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) --  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Phase 2 data for CX-2009, a conditionally activated antibody drug conjugate (ADC) targeting CD166, will be presented at the San Antonio Breast Cancer Symposium on December 8th. The poster details the results from patients treated with monotherapy praluzatamab ravtansine for the treatment of advanced HR+/HER2- breast cancer and triple negative breast cancer (TNBC).

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

Ensysce Biosciences

NeuroOne Medical Technologies Corp

Nexalin Technology Inc

Taysha Gene Therapies

Biotech penny stocks to watch this week. Are they a buy now?

Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

CytomX Therapeutics (NASDAQ: CTMX ) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (NASDAQ: REGN ). This strategic partnership will see the two companies working together on the development of cancer therapies.

Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?

- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody ® and Regeneron's Veloci-Bi ® platforms -

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Regeneron Pharmaceuticals

Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody® and Regeneron's Veloci-Bi ® platforms CytomX to receive $30 million upfront payment with the potential for up to $2 billion in research, development, regulatory and sales-based milestones TARRYTOWN, N.Y. and SOUTH SAN FRANCISCO, Calif.

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Peter Lawson - Barclays Etzer Darout - BMO Capital Markets Mara Goldstein - Mizuho Group Mitchell Kapoor - H.C. Wainwright Joseph Catanzaro - Piper Operator Good day, and thank you for standing by.

CytomX Therapeutics, Inc. (CTMX) Q3 2022 Earnings Call Transcript

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates

- Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 -

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is anticipated in the second half of 2023 -

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a corporate update.

CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022

- Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb -- BMS-986249 Phase 2 study ongoing -

CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249

- Presentation at World ADC Conference in San Diego -

CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Chau Cheng - Vice President of Investor Relations & Corporate Communications Sean McCarthy - Chief Executive Officer & Chairman Carlos Campoy - Chief Financial Officer Conference Call Participants Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets Supawat Thongthip - Mizuho Mitchell Kapoor - H.C. Wainwright Operator Good afternoon, everyone.

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2022 Results - Earnings Call Transcript

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.78% and 1.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

- Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 -

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will virtually participate in the following investor conferences in August.

CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences

CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a corporate update.

CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

CytomX Therapeutics Inc (NASDAQ: CTMX) is restructuring its business to prioritize internal investments in its emerging pre-clinical and early clinical pipeline. The company will cut 40% of its workforce.

CytomX Therapeutics Cuts Workforce, Extend Cash Runway Into 2025

- Company to focus internal efforts on wholly-owned next-generation conditionally activated therapeutics, including IFN alpha-2b cytokine and EpCAM-directed ADC, INDs planned for 2023 -

CytomX Therapeutics Provides Strategic Update

CytomX Therapeutics Inc's (NASDAQ: CTMX) Phase 2 study of praluzatamab ravtansine in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A) met its primary efficacy endpoint of confirmed objective response rate (ORR).

CytomX's Breast Cancer Candidate Meets Primary Goal Of Objective Response Rate

- Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer -

News for CytomX Therapeutics Stock (CTMX)